salivary gland carcinoma (Cancer)

Search with Google Search with Bing
Information
Disease name
salivary gland carcinoma
Disease ID
DOID:0050904
Description
"A salivary gland cancer that has_material_basis_in epithelial cells." [url:http\://en.wikipedia.org/wiki/Salivary_gland_neoplasm, url:http\://www.cancer.gov/dictionary?CdrID=45963]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT02393820 Completed Phase 2 Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma August 26, 2013 October 2019
NCT03132038 Completed Phase 2 Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck March 24, 2017 October 20, 2021
NCT03602079 Completed Phase 1/Phase 2 Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene July 16, 2018 January 12, 2022
NCT03749460 Completed Phase 1/Phase 2 Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers January 15, 2019 November 5, 2023
NCT05075980 Recruiting Phase 2 HEADLIGHT: Hypofractionated Proton Therapy for Head and Neck Cancers February 16, 2022 November 15, 2026
NCT03942380 Recruiting N/A Cell-free Tumor DNA in Head and Neck Cancer Patients February 1, 2017 February 1, 2025
NCT02628067 Recruiting Phase 2 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) December 18, 2015 May 4, 2027
NCT03942653 Recruiting Phase 2 Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma May 30, 2019 May 2024
NCT04832438 Withdrawn Phase 2 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma December 18, 2030 June 18, 2034
Disase is a (Disease Ontology)
DOID:8850